Hyaluronic Acid in Papillary Reconstruction
Minimally Invasive Treatment for Papillae Deficiencies in Esthetic Zone Using Hyaluronic Acid
1 other identifier
interventional
15
0 countries
N/A
Brief Summary
Hyaluronic acid (HA) has been used as a dermal filler in medicine for many years. It also has umpteen benefits in terms of aiding in rapid healing and resolution of inflammation. Thus in the present study, HA has been used at the test site to fill papillary recession defects. At the control site saline was injected as the placebo.
Trial Health
Trial Health Score
Automated assessment based on enrollment pace, timeline, and geographic reach
participants targeted
Target at below P25 for phase_4
Started Nov 2012
Typical duration for phase_4
Health score is calculated from publicly available data and should be used for screening purposes only.
Trial Relationships
Click on a node to explore related trials.
Study Timeline
Key milestones and dates
Study Start
First participant enrolled
November 1, 2012
CompletedPrimary Completion
Last participant's last visit for primary outcome
October 1, 2015
CompletedStudy Completion
Last participant's last visit for all outcomes
October 1, 2015
CompletedFirst Submitted
Initial submission to the registry
August 12, 2016
CompletedFirst Posted
Study publicly available on registry
August 23, 2016
CompletedAugust 23, 2016
August 1, 2016
2.9 years
August 12, 2016
August 17, 2016
Conditions
Outcome Measures
Primary Outcomes (2)
the papillary recession reduction (pRecRed).
. papillary recession depth (distance from the contact point to gingival margin was measured to the nearest millimeter- CP -GM)
6 month
percentage papillary coverage(PPC
The formula used to calculate the percentage papillary coverage was as follows- Baseline (CP-GM) - 6 month (CP-GM) \---------------------------------------------- x 100 Baseline (CP-GM)
6 month
Study Arms (2)
HA filler group
ACTIVE COMPARATOR6 weeks after the initial therapy, patients were scheduled for the procedure.16 Local Anesthetic solution (2% Lignocaine HCl with adrenaline 1:80000) was administered.17 About 0.2 ml of a commercially available hyaluronic acid based gel was injected 2-3 mm coronal to the apical tip of the receded interdental papilla . Injections were performed using 23 gauge X 25mm intraoral injection needles . The concentration of HA gel used was 20 mg/ml.6 The area was gently massaged to ensure that the filler was uniformly distributed. Care was taken to fill each papilla to full correction (100% of defect). After the treatment the individual patient syringes were capped and stored in a refrigerator with patient names and details. The needle was discarded. Patients were seen three weeks after the initial treatment and if augmentation was still deemed necessary, another injection of 0.2ml was injected up to three times
saline filler group
PLACEBO COMPARATORwith saline same protocol was performed as mentioned in test group
Interventions
Papillary augmentation with HA dermal fillers was considered as the test group
Eligibility Criteria
You may qualify if:
- Age group of 25-75 years, with at least one pair of similar bilateral, Nordland's class I and class II loss of interdental papillae in the maxillary anterior region, radiographic evidence of sufficient interdental alveolar bone (i.e. distance between alveolar crest and contact point ≤ 5mm), pocket probing depth ≤ 4mm, systemically healthy patients, patients willing to participate in the study and patients with esthetic concerns
You may not qualify if:
- Patients with known allergy to hyaluronic acid, patients with poor plaque control.(≥20% O'Leary plaque index), medically compromised patients, pregnant and lactating women, history of smoking, who had received a crown or pontic on one or both teeth involved in the interproximal space, interproximal spaces next to teeth that included root grooves, furcations, Miller's tooth mobility index \>18, open contacts, probing depths \>3 mm, and radiographic evidence of pathology, with translocated or tilted teeth, and who had undergone papillary regeneration procedures in the area selected previously
Contact the study team to confirm eligibility.
Sponsors & Collaborators
Study Design
- Study Type
- interventional
- Phase
- phase 4
- Allocation
- RANDOMIZED
- Masking
- DOUBLE
- Who Masked
- PARTICIPANT, INVESTIGATOR
- Purpose
- TREATMENT
- Intervention Model
- SINGLE GROUP
- Sponsor Type
- OTHER
- Responsible Party
- SPONSOR
Study Record Dates
First Submitted
August 12, 2016
First Posted
August 23, 2016
Study Start
November 1, 2012
Primary Completion
October 1, 2015
Study Completion
October 1, 2015
Last Updated
August 23, 2016
Record last verified: 2016-08